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Abstract—Hundreds of millions of people worldwide are af-
fected by viral infections each year, and yet, several of them
neither have vaccines nor effective treatment during and post-
infection. This challenge has been highlighted by the COVID-
19 pandemic, showing how viruses can quickly spread and
impact society as a whole. Novel interdisciplinary techniques
must emerge to provide forward-looking strategies to combat
viral infections, as well as possible future pandemics. In the
past decade, an interdisciplinary area involving bioengineering,
nanotechnology and information and communication technology
(ICT) has been developed, known as Molecular Communications.
This new emerging area uses elements of classical communication
systems to molecular signalling and communication found inside
and outside biological systems, characterizing the signalling
processes between cells and viruses. In this paper, we provide an
extensive and detailed discussion on how molecular communica-
tions can be integrated into the viral infectious diseases research,
and how possible treatment and vaccines can be developed
considering molecules as information carriers. We provide a
literature review on molecular communications models for viral
infection (intra-body and extra-body), a deep analysis on their
effects on immune response, how experimental can be used by
the molecular communications community, as well as open issues
and future directions.
Index Terms—Communicable diseases, Infection, Molecular
communications, Virions, Virus.
I. INTRODUCTION
The COVID-19 pandemic shocked the world by demon-
strating the severity of the viral infection and how it can
disrupt society by impacting human health as well as global
economies. As of September 2020, more than 34 million
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people have contracted the disease resulting in just over a
million deaths, with a a mortality rate of approximately 4%.
During the first months of the pandemic, global stock markets
experienced their worst crash since 1987, in the first three
months of 2020 the G20 economies fell by 3.4% year-on-
year, an estimated 400 million full-time jobs were lost across
the world, and income earned by workers globally fell 10%,
where all of this effects is equivalent to a loss of over US$3.5
trillion [1]. As a result, governments around the world have
quickly formulated new recovery plans, where for example
in the EU, an investment of 750 billion euros is set to bring
the continent back to normality within the first half of the
decade (this also includes funding for research on COVID-
19) [2]. Despite these investments, the world must prepare for
not only coping with this new disease and its various effects
on the human health, but also seeking for novel technologies
that can help minimise, or even block, future pandemics.
The SARS-CoV-2 virus itself is likely to remain a challenge
for the next couple of years despite the development of
vaccines [3]. First, it is challenging to develop a vaccine
that is effective for different virus strains and their mutations.
Besides, for patients that are infected, the detrimental effect of
the virus in the human body can leave lifelong consequences
to tissues and organs. To give an example of the difficulty
of eradicating viruses, historic virus such as influenza had its
first pandemic in the 16th century and is still considered a
global health challenge till this present day [4]. Therefore,
constant efforts in new robust vaccines, as well as drugs, are
continuously being sought and this requires the development of
new technologies that focus on the mechanisms of infections,
and in particular the virus molecular relationships with the
host cells [5].
In the past 10 years, an interdisciplinary research area
known as Molecular Communications has been developing,
and it bridges the areas of communication engineering and
networking, molecular biology, as well as bioengineering [6],
[7]. This area focuses on realising radical new technology
for subtle sensing and actuation capabilities inside the human
body through a network of micro- and nano-sized devices
[8], [9]. These devices can use the existing natural signalling
of cells and tissues to interact, as well as communication
with the human body. The main advantage is the ability to
increase the biocompatibility of implantable systems, and one
of the ways to realise this is to integrate communication
system engineering with systems and synthetic biology [8],
[9]. This novel research area can have a central role to combat
current and future pandemics, not only for understanding
new insights into the viral properties and characteristics, but
also for novel treatments [10], [11], [12], [13]. Molecular
communications can contribute to (a) the characterisation of
the virus propagation within the body, (b) understanding the
mechanism used by the virus to enter the human body, or
mechanism of expulsion, and (c) elucidating how the airborne
virus propagates in the air. Additionally, although not covered
in this survey, molecular communications is at the foundations
of the Internet of Bio-Nano Things paradigm [8], where
communication between engineered cells for viral infection
detection/therapy is intercepted, interpreted, and manipulated
by bio-cyber interfaces that can transmit data to cloud-based
digital healthcare services [14].
However, the literature on molecular communications does
not provide a wide range of work that tackles the issue of
viral infection as a whole. Even though there are models
for molecular communications for bacterial infection [15],
[16], there have not been any surveys proposed for molecular
communications models of viral infections. To date, molecular
communications models for viral infection includes multi-hop
transfer of genetic content through diffusion over extracellular
channels [17], viral propagation in the air [18], [19], propa-
gation within the respiratory tract [20], as well as interactions
with host cells [21]. Even though these models are very
interesting and provide a formidable representation of biology
through the glasses of a molecular communications researcher,
the issue of virus propagation and the infection itself are
much more complex. First, models must gather all necessary
information about the infection process, which comprises of
the replication of viruses and intra-body propagation, going
down to the interaction of genes and host cells, as well as
the virus spike proteins effects to binding host cell receptors.
Secondly, virology is a very active research area and has
collected many resources over the years (data and tools) that
can benefit molecular communications research. In order to
develop research work with a strong societal impact in order
to tackle viral infectious diseases, molecular communications
researchers are required to bridge the gap between communi-
cation theory and experimental biology, and in particular the
use of available data.
This paper presents a literature review and analysis of exist-
ing models and data for molecular communications. The goals
of this paper are as follows: 1) to provide how the infectious
disease is currently modelled using molecular communica-
tions; 2) to provide a deep analysis on the existing models to
provide a direction on how they should be improved, looking
from a biological standpoint; 3) to provide initial guidelines
on what experimental data can be used and how they should
be integrated to molecular communications models, and 4)
to identify the main challenges and issues that the community
should focus on moving forward. We recognise that molecular
communications can support not only the understanding of
infectious diseases, but it can also elicit the development of
novel technologies for both sensing and actuation in the body
based on how viruses propagate, are transmitted and received
by host cells.
The paper has the following contributions:
• A literature survey on models of infectious diseases for
intra-body and extra-body molecular communications:
We present a deep analysis on existing molecular com-
munications models looking at how to address the issue
of bridging these models closer to the existing biological
literature and data on infectious disease. For the intra-
body models, we investigate the virus entry mechanism,
the virus spread and the immune system response. For the
extra-body models, we look into the transmitter, channel
and receiver processes for human-human propagation of
infection.
• Analysis of existing open data on viral infections that can
be utilised by molecular communications researchers: We
collect a variety of data from a number of sources that
we believe can be used by the community to gain a better
understanding of viral infections. These data vary from
the genetic information of a variety of viruses to the
molecular structure and the effects on the hosts, e.g., the
immune markers and host infection impact. We focus on
a selection of viruses that includes the SARS-CoV (1-
2), MERS-CoV, Ebola (EBOV), Dengue (DENV), Zika
(ZIKV) and hepatitis C (HCV).
• Overview on open issues and challenges: Based on the
many opportunities for research in molecular communi-
cations and infectious diseases, we provide five different
points where we present a deep analysis aiming to high-
light what are the main topics to drive future research
on molecular communications. We include discussion
about: 1) linking experimental data to molecular commu-
nications models, 2) novel intra-body viral intervention
techniques, 3) emerging technologies for infection thera-
nostics (therapy and diagnostics), 4) bridging molecular
communications and bioinformatics tools, and 5) novel
molecular communications models.
The paper structure is as follows. Section II presents the
background information on infectious disease. Section III
presents a literature survey on viral models for infections
in intra-body and extra-body settings. Section IV presents a
set of experimental data that can be exploited in molecular
communications. Section V presents the open issues and chal-
lenges for the future of molecular communications research
on communicable disease. Finally, Section VI concludes the
study.
II. BACKGROUND INFORMATION ON INFECTIOUS
DISEASES
In this section, we go through several known communicable
viral diseases and provide examples of devastating outbreaks
in the 21st century. We select seven viruses that, at the time
of writing this paper, do not have a licensed vaccine for
treatment or where the intervention mechanisms are only used
to alleviate symptoms of the hosts. Our survey focuses on three
families of viruses, and this includes Coronavirus, Filovirus,
and Flavivirus.
A. Coronavirus
Coronaviridae is a family of viruses that includes SARS-
CoV-1, MERS-CoV and SARS-CoV-2. The most severe
virus in this family is the SARS-CoV-2. Example properties
of SARS-CoV-2 include asymptomatic infection to severe
pneumonia and replicates through a variety of cells that
exhibit Angiotensin Converting Enzyme 2 (ACE2) expression
(a number of these cells are found in the respiratory tract, and,
in particular, deep in the alveolar regions). SARS-CoV-1 and
MERS-CoV are known to cause severe pneumonia with high
replication rates in the respiratory tract. The immune response
to the three different viruses is also very different. In the case
of SARS-CoV-1 and MERS-CoV, antibodies response at an
early stage of the infection process. However, this is not the
case for SARS-CoV-2, where the symptoms from the infection
process can take up to two weeks.
There are several differences between SARS-CoV-1,
MERS-CoV and SARS-CoV-2 in the spreading process. While
SARS-CoV-1 and MERS-CoV are known to develop se-
vere pneumonia, they have exhibited limited person-to-person
spreading, which is very different from SARS-CoV-2 [22].
Even though promising solutions for vaccines targeting SARS-
CoV-2 are in the testing phase, their efficacy is yet unknown
or unpredictable. Besides vaccines, the existing immune-based
treatment (e.g., plasma transfusion) is only found to have
temporary effects [23]. On top of that, there are other several
unknowns about how SARS-CoV-2 affects different organs,
indicated by clinical data [24], [25].
B. Filovirus
Filoviridae family of viruses comes from the thread-like
structure of the virus that also contains many curvy branches
[26]. The most common, or well known, is the EBOV (zaire
ebolavirus). Currently, there is only one FDA approved Ebola
vaccine (approved in 2019 [27]) that has a successful perfor-
mance of around 70% to 100% efficiency, and this is the rVSV-
ZEBOV vaccine [28]. This vaccine acts as the glycoprotein
duplicate. Once expressed in the host, it will activate the
immune system response. The vaccine was used for clinical
trials in West-Africa, to cope with the local 2016 pandemic.
However, research is still on-going to analyse the vaccine
response for virus genome mutation.
C. Flavivirus
Flaviviridae family of viruses is mainly characterised by the
yellow complexion found on the hosts after infection (hence
yellow fever), and by the transmission mode of arthropod
vectors (mainly ticks and mosquitoes). We analyse three types
of virus in this family, and they include DENV, ZIKV and
HCV.
The single positive-stranded RNA DENV is mosquito-borne
and mostly found in countries in the centre global hemisphere,
where the warm temperature is an ideal location for mosquito’s
habitation. The virus has not always been found to transmit
through mosquitoes. Many years ago, the transmission mode
was sylvatic, meaning contraction from wild animal contacts.
Over the past 20 years, dengue fever has increased dramati-
cally, affecting more than 390 million people each year. The
main molecular characteristic of this virus is the genomic RNA
surrounded by numerous protein layers.
ZIKV is transmitted and similarly affects the host cells
to the DENV since both share a distinct genetic component.
However, the fever from ZIKV infection is more potent and
is found to impact developing fetus in pregnant women, and
can lead to microcephaly. This virus is relatively new. Hence,
no vaccine is available. Similarly to DENV, there are seven
non-structural proteins, three structural proteins and a positive
single-stranded RNA genome. However, the main difference
is the mechanism in which the host cells reacts to the genome
upon infection, where the infected cells are found to progress
into the swollen stages leading to cell death. This is only
possible through the virus gene expression and the inability
of the host cell to protect itself against virus binding through
the concentration of the IFITM3 protein.
Lastly, HCV is also a single-stranded RNA virus. Infected
hosts can have symptoms that include occasional fever, dark
urine, abdominal pain and yellow-tinged skin. To date, the
virus has infected nearly 71 million people worldwide. Even
though simpler in structure, there is still no vaccine for ECV
because of its numerous genotypes derived from their protein
structure, or even proper medical intervention techniques.
These efforts would help minimise damaging effects to the
liver, the organ most damaged by this virus in infected patients
[29].
D. Viruses Structural Data
In Table I, we collect the main quantitative information
about the viruses discussed in this section. In order to obtain
an accurate representation of the virus propagation and rela-
tionship with the host, we analyse the viral concentrations in
specimens, the characteristics of virions and the virus detection
for each type of virus. Different basal, or steady-state concen-
trations, are provided for different settings where specimens
were collected. This will help to figure out initial parameter
values in reaction-diffusion models that account for virus
interactions with the host. Next, we present the characteristics
of the viruses, which state the structural dimensions (useful
for quantifying the diffusion profile), genetic profile (useful
for transcription of gene information between the virus and
host cells), as well as types of proteins on the virus surfaces
(useful for accounting the reception of the virus by a cell by
means of ligand biding). Lastly, we provide many detection
mechanisms that were used, and are useful, for measuring the
viral concentration on specimens.
III. MOLECULAR COMMUNICATIONS FOR VIRAL
INFECTIONS
In this section, we present the literature review on the intra-
body- and extra-body molecular communications models.
A. Intra-body Molecular Communications Models
1) Virus Entry Mechanisms: The molecular communica-
tions paradigm gives us a clear understanding of how the virus
TABLE I
AVAILABLE QUANTITATIVE DATA TO SUPPORT MOLECULAR COMMUNICATIONS MODELLING




Nasopharyngeal aspirates – mean values of 2.3×105 RNA
copies/mL, 1.9×107 copies/mL, and 9.8×104 copies/mL on days
5, 10, and 15, respectively (collected from 14 patients)
Stool – a mean value of 1.0×107 copies/mL on day 10 (collected
from 1 patient)
SARS-CoV-2:
Lower respiratory specimens (sputum samples) – 641-1.34×1011
copies/mL, with a median of 7.52×105 (collected from 80 patients)
Posterior oropharyngeal saliva – a median of 1.58×105 copies/mL
Upper respiratory specimens (nasal and throat swabs) – cycle
threshold (Ct) values 19-40 (collected from 14 patients); Ct val-
ues are inversely related to viral RNA copy number, with Ct of
30.76, 27.67, 24.56, and 21.48 corresponding to 1.5×104, 1.5×105,
1.5×106, and 1.5×107 copies/mL
Enveloped, spherical, 60-140 nm in di-
ameter with spikes of about 9-12 nm
Genome: 30 kb positive-sense, single-
stranded RNA















MERS-CoV Lower and upper respiratory specimens (sputum or tracheal
aspirate, and throat-swab) – a median of 1.62×107 RNA copies/mL
in the severe group and 3.47×105 copies/mL in the mild group
(depending on whether oxygen supplementation was used) (P =
0.06) (collected from 17 patients)
Around 100 nm in diameter
Genome: (+)ssrNA, 30 kb (20-33
kb) enveloped, positive-sense, single-
stranded RNA virus














EBOV Serum – up to 1010 RNA copies/mL in samples from the patients
who died; up to 108 within the first 8 days after the onset of
symptoms;
Viremia classified as low, intermediate, or high according to the viral
load (<1.73×104, 1.73×104-8.7×106, and > 8.7×106) GEQ/mL
(genome equivalent per mL), respectively) (collected from 632
patients)
Filamentous, 970 nm long, 80 nm in
diameter, enveloped
Genome: approximately 19 kilobase
negative-sense, single-stranded RNA
Proteome: 7 sequentially arranged pro-
teins












DENV Serum – 103-1011 RNA copies/mL (collected from 228 patients,
whose data were stratified by infecting dengue serotype (DENV-1,
DENV-2, or DENV-3) and by immune status and clinical manifes-
tation (primary infection dengue fever, secondary infection dengue
fever, or secondary infection dengue hemorrhagic fever)
Around 50 nm in diameter, icosahedral,
enveloped
Genome: 10.7 kilobase positive-sense,
single-stranded RNA
Proteome: single polyprotein, co- &
post-translationally cleaved into 11 ma-
ture proteins













ZIKV Plasma – 6.30×102 RNA copies/mL
Urine – 1.26×103 RNA copies/mL
Semen – 3.98×108 RNA copies/mL (collected 2 weeks after
symptom onset from a 32-year-old man) and up to 1.58×109 RNA
copies/mL measured (collected from 12 men in French Guiana with
ZIKV infection)
Plasma, urine, and saliva – ZIKV RNA found in the saliva of only
the woman; ZIKV remained detectable in their plasma for about 2
weeks, while the urine of the man was consistently positive until
day 14 and that of the woman until day 25; The greater virus load
in the urine observed in the man (collected from a 69-year-old man
and 66-year-old-woman)
Enveloped, spherical, 50 nm in diam-
eter with an electron dense core of 30
nm
Genome: 10.8 kb positive-sense,
single-stranded RNA
Proteome: single polyprotein, co- &
post-translationally cleaved into 11 ma-
ture proteins













HCV Serum – 2×105-1.61×107 RNA copies/mL (collected from 38
chronically infected patients – 19 infected by genotype 1 isolates
(1a and 1b), 13 by nongenotype 1 isolates (including genotypes 2
a/c, 3a, and 4), and 6 coinfected by genotype 1 and 6 isolates)
Around 50 nm in diameter, icosahedral,
enveloped
Genome: 9.6 kilobase positive-sense,
single-stranded RNA
Proteome: single polyprotein, co- &
post-translationally cleaved into 10 ma-
ture proteins
RNA Transcript: 5’ internal ribosomal









acts and distributes within the body over time. In the context of
communications, the virions are considered as information car-
riers, which propagate messages (genome) from the location
of transmission until the location of the reception, which can
be the host cells in specific organs or tissues. The information
conveyed by the virions is the infection action.
In theory, a single virion is enough to enter the body
and initiate a viral infection, provided that the host cells are
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Fig. 1. Molecular communications channels of viral intra-body spread. After (a) translocation across the epithelium, the virus spread throughout the body
utilising (b) the circulatory system, (c) nervous network, and (d) cell-released EVs that carry viral components as their cargo and deliver to other cells,
eventually causing systemic infection.
accessible to the viral binding process. Besides the accessible
cells being susceptible to infection – they must also express the
receptors to which the virus binds, and permissive to infection
– which means they must contain protein and machinery
necessary for virus replication [48].
If the virus enters the host through the respiratory tract,
gastrointestinal tract, genital tract or optical tract, the main
barrier between the virus and internal environment of the body
is the epithelial cells – the layer of cells that line the outer
surfaces of organs and blood vessels and the inner surfaces
of cavities (Fig. 1a). The epithelial cells of the respiratory
tract are targeted by SARS-CoV (1-2) and MERS-CoV viruses
as the most common portal of entry. Unlike SARS-CoV (1-
2), which exclusively infects and releases through the apical
route1, MERS-CoV can spread through either side of human
bronchial epithelial cells. SARS-CoV (1-2) and MERS-CoV
viruses contained in larger droplets are deposited in the upper
respiratory tract (the nose, nasal passages, sinuses, pharynx,
and larynx), while smaller aerosolised particles or liquids
are transferred into the lower respiratory tract (the trachea,
bronchi, and lungs). EBOV targets the epithelial cells as a
final attack though, after infecting fibroblasts of any type
(especially fibroblastic reticular cells), mononuclear phago-
cytes (with dendritic cells more affected than monocytes or
macrophages) and endothelial cells. On the other hand, if
the virus is delivered through penetration of the skin (e.g.,
DENV- or ZIKV infection from a mosquito bite), wounds
or transplantation of an infected organ (e.g., HCV infected
organ), the epithelium is bypassed.
Viruses have evolved strategies to translocate across the
epithelial barrier and act as pathogens. They can enter and
infect or cross epithelial cells through the following three
modes [49]: 1) Endocytosis and transcytosis (without infec-
1The apical membrane faces the external (luminal) compartment and con-
tains proteins that determine secretion and absorption, whereas the basolateral
domain faces the internal (systemic) compartment (tissues and blood).
tion), 2) Polarised surface entry and infection by fusion, and
3) Endocytosis and endosomal fusion with infection.
Endocytosis and transcytosis (without infection) are, re-
spectively, entry- and intracellular transport mechanisms for
specific viruses, such as poliovirus, reovirus and human im-
munodeficiency virus 1 (HIV-1), performed by specific lym-
phoid areas of the gastrointestinal tract covered by specialised
epithelial cells known as M cells. During endocytosis, which
is initiated at clathrin- and caveolin-coated pits and vesicles,
or lipid raft microdomains, the host cell engulfs the virus.
During transcytosis, the host cell transports the virus through
its cytosol and eventually eject the virus at the opposite side of
the membrane. Polarised surface entry and infection by fusion
is an entry mechanism for enveloped viruses, including SARS-
CoV (1-2) and MERS-CoV, whose genome is surrounded by
a capsid and a membrane [50]. The virus fuses either to the
apical membrane or the basal membrane of the epithelial
cell and transfers the genome into the cytoplasm. Lastly,
endocytosis and endosomal fusion with infection is an entry
mechanism for both enveloped and naked (the genome is
surrounded only by a capsid) viruses, including EBOV. Other
examples include influenza virus types A and C, bovine coro-
navirus, hepatitis A (HAV), vesicular stomatitis virus (VSV),
primary herpes simplex virus (HSV), human cytomegalovirus
(HCMV), adeno-associated virus (AAV)-2, simian virus 40
(SV40), measles virus, Semliki Forest virus (SFV), Sindbis
virus, Jamestown Canyon (JC) polyomavirus, parvovirus, and
the minor group of human rhinoviruses (HRV). These viruses
internalise and retain in transport vesicles. To gain access to
the cytoplasm, their genome has to leave the vesicle by which
it was taken up, usually by penetrating the host cell cytosol
through fusion from an endosome.
We refer to modelling viral translocation across the epithe-
lial barrier as MODEL 1. Despite all differences in the mecha-
nisms involved in this model, the transfer process always starts
with the virions binding to the target receptors. Upon binding,
the virions become fused with- or internalised into the host cell
cytosol. Recycling/negative feedback mechanisms regulate the
number of surface bonds between the virions and the receptors.
This leads to the following chemical kinetic model represent-
ing the viral load/concentration at the extracellular space Vo(t),
the viral load at the epithelial host cell membrane (host cell-
bound virions) Vb(t), and the viral load in the host cell cytosol




=β [Vin − cVo(t)]−
−aVo(t) [nvN(t) + nvN0(t)− Vb(t)] (1)
dVb(t)
dt





where β is the ratio of the volume of the considered medium
containing Vo(t) and the host cell volume, Vin is the initial
viral load at the extracellular space, c is a constant rate of viral
clearance per virion by mechanisms such as immune elimina-
tion (corresponding to a virion half-life tV1/2 = ln(2)/c), nv
is the total number of the viruses that can be bound, N(t) is
the total number of occupied receptors per unit volume at the
membrane, N0(t) is the total number of unoccupied receptors
per unit volume at the membrane, a = a0/nv is the rate
defined through the maximal binding rate a0 measured when
none of the viruses is bound to the membrane, and ki is the
virus fusion or internalisation rate [51]. Vin can have steady-
state values considering different cases listed in Table I, where
viral concentration values are available. Even with the other
model variables that can be obtained from the literature, values
for Vin set the range where the solutions of the equations
converge.
The presented model can be considered accurate if the data
of the concentration of viral ligands interaction with the host
cell receptors are available.
2) Virus Spread: After translocation across the epithelial
barrier, the virus infects and replicates at the site of infection,
causing localised infections, and/or initiates infection through
one organ and then spreads to other sites, causing systemic
infections [48].
A straightforward way to describe the viral load (V (l)(t))
dynamics in a localised infection is to use the target cell-
limited model [52]. This model neglects intracellular processes
and takes into account uninfected susceptible target cells (T )
and infected virus-producing cells (I) within an observed
organ. The basic model is formulated by the following system
of nonlinear ordinary differential equations (ODEs) [53]:
dV (l)(t)
dt




= kV (l)(t)T (t)− δI(t), (5)
dT (t)
dt
= λ− dT (t)− kV (l)(t)T (t). (6)
The target cells become infected cells which produce virus
with production rate p, k is a constant infectivity rate, δ is a
constant rate of death in infected cells (corresponding to an
infected cell half-life of tI1/2 = ln(2)/δ), λ is a constant rate
of uninfected target cells production, and d is a constant rate
of uninfected target cells death (corresponding to a target cell
half-life of tT1/2 = ln(2)/d). This model can be applied to
analytically describe the local spread of any family of viruses.
Apart from the viruses considered in Section II, rhinovirus
and papillomavirus are examples of viruses that cause only
a localised infection. Rhinovirus infects the epithelial cells
of the upper respiratory tract and replicates there, whereas
papillomavirus infects the skin and replicates in the epidermis.
Describing the viral load dynamics in a systemic infection is
more challenging since the virus spreads to other organs using
mechanisms like the bloodstream (hematogeneous spread),
neurons (neurotropic spread), or extracellular vesicles.
Viruses can enter the bloodstream either directly through
inoculation into an animal or insect bites (e.g., DENV and
ZIKV), or through the release of virions produced at the
entry site into the interstitial fluid (e.g., coronaviruses) [48].
This fluid can be taken up by lymphatic vessels that lead
back to lymph nodes. Although immune system cells filter
the interstitial fluid within the lymph nodes, some virions
escape immune cells and continue within the interstitial fluid,
which is eventually returned to the bloodstream. The virus
takes advantage of the blood distribution network for the
propagation of the virions from a location they are injected
into the blood flow to a targeted site within reach of the
cardiovascular system. Advection and diffusion are the mass
transport phenomena in the cardiovascular system [54]. As a
result of advection, the virions are transported by the flow of
the blood at different velocities in different locations of the
cardiovascular system. As a result of diffusion, the virions
are transported from a region of higher concentration to a
region of lower concentration. This pattern of motion follows
the Brownian motion spread in the blood.
To leave the circulatory system and infect other sites in
the body, the virions need to penetrate the blood vessel walls
made of the endothelial cells (Fig. 1b). We refer to modelling
viral translocation across the endothelial barrier as MODEL
2. Viruses enter and then infect or cross endothelial cells by
endocytosis at the apical (luminal) membrane. When infecting
the endothelial cell, the virions penetrate the host cell cytosol
by fusion from endosomes. However, if the virus crosses the
endothelial cell, the virions are transported via intracellular
trafficking and ejected from the basolateral (abluminal) mem-
brane into the extracellular space. This leads to the following
chemical kinetic model [55]:
∂V (b)(r̄, t)
∂t
= −(c+ k1f )V (b)(r̄, t) + k1bV
(b)






(b)(r̄, t)− (k1b + k2f )V
(b)
BV (r̄, t) +
+ k2bV
(b)












− (k3f + kp)V
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EV (r̄, t), (11)







represent the viral load
at the extracellular space (luminal side), the viral load at the
endothelial host cell membrane (host cell-bound virions), the
viral load in the host cell endosomes, the viral load in the
host cell cytosol that penetrated the endosomes, and the viral
load at the extracellular space (abluminal side), at point r̄ and
time t, r̄ ∈ ∂D (∂D is the set of points over the endothelial
host cell membrane). kif and k
i
b, i = 1, 2, 3 are forward and
backward reaction rates in ms−1 and s−1, respectively, and kp
is the endosome penetration rate in s−1.
The virion transport mechanism across the blood vessel
walls imposes a boundary condition for advection-diffusion
in the vessel. Concentrations for different types of viruses in
plasma and serum from Table I can be used here as initial
values. These values do not take into account the dispersion
in the blood and shall be considered in entering points to the
blood vessels. This mechanism is modelled by a continuous-
time Markov chain framework leading to the following general




































where D is the diffusion coefficient in m2s−1 of the virions in
the blood, k′ = k2b +k
3
f +kp, ∇ is the gradient operator, (·) is
the inner multiplication operator, and n̂ is the surface normal
at r̄ ∈ ∂D pointing towards the vessel luminal side. The virion
advection-diffusion in the observed blood vessel can then be
modelled by the Fick’s second law:





subject to the boundary condition (12). The release rate of the
virus at point r̄ is given by the source term S(r̄, t) (virion
s−1m−1), ∇2 is the Laplace operator, and cb is a constant
rate of viral clearance in the blood. The blood is assumed
to have a laminar flow in the axial direction with uniform
velocity profile v̄(r̄) = vâz ms−1, where âz is the axial unit
vector. The fundamental characteristic function for advection-
diffusion called the concentration Green’s function is analyt-
ically derived in terms of a convergent infinite series [55].
The obtained concentration Green’s function is coupled to the
boundary condition given in (12) and provides a useful tool
for prediction of the viral load in blood vessels.
Viruses rarely enter into neurons directly to evoke the
neurotropic viral spread (Fig. 1c). We refer to modelling
neurotropic viral spread as MODEL 3. Viruses first replicate
locally and then infect nerves associated with the tissue [48].
Thus, viruses first infect neurons of the peripheral nervous
system, and then gain access to the central nervous system.
There is emerging speculations that the central nervous system
may be involved during SARS-CoV-2 infection, where neuron-
to-neuron transmission route is used to spread the virus [56].
Other examples of neuroinvasive viruses include several herpes
viruses (e.g., herpes simplex virus) and poliovirus, which is
weakly neuroinvasive, and rabies virus, which requires tissue
trauma to become neuroinvasive. The literature is, however,
very sparse concerning biological models on the neurotropic
viral spread. Therefore, we advocate for the consideration
of detailed biological models where the characterisation of
viral spread throughout the nervous system is considered in
more details. This includes addressing secondary mechanisms
evolved by some viruses to help them replicate and spread
(e.g., binding to a host cell protein called dynein which then
transports viral capsid to the neural nucleus for replication).
Extracellular vesicles (EVs) are exchanged between all
cells and emerge as the novel, yet obscure cell-to-cell com-
munication mediators. EVs vary in size (50–5000 nm) and
contain and transport transmembrane proteins in their lipid
bilayer, as well as the cytosol molecular components from the
parental cell. The latter includes functional proteins, lipids,
and genetic materials [e.g., messenger RNA (mRNA), non-
coding RNA (ncRNA), and DNA] [57]. EVs can also transfer
functionally active cargo and have the ability to participate in
biological reactions associated with viral dissemination – the
evidence exists for HCV, HIV, and Epstein-Barr virus (EBV)
– and immune response (Fig. 1d) [58].
EVs and viruses share common features in their size,
structure, biogenesis and uptake [59]. EVs either favour viral
infections or limit them, by prompting viral spread or modulat-
ing the immune response, respectively. When leveraging viral
infection, virus-associated EVs deploy mechanisms such as the
delivery of (a) proteins that make the cell more susceptible
to infection, (b) viral receptors to cells that are devoid of
these receptors thus allowing cells to be infected, (c) nucleic
acids that improve and sustain the production of a virus, and
(d) molecules that eliminate the host protein relevant for an
antiviral response [59], [58]. On the other hand, different
mechanisms can be activated by the EVs released by infected
cells to prompt an immune response against viruses. The most
important mechanisms are the spreading of viral antigens via
EVs, and the transfer of cytosolic proteins and nucleic acids
involved in antiviral responses. Nonetheless, it is still unclear
what cell conditions and virus types release EVs that favour
or fight infection.
For initial molecular communications system modelling, it
seems that viral components hijack the EV secretory routes
to exit infected cells and use EV endocytic routes to enter
uninfected and immune system cells [58]. We refer to mod-
elling EV-based viral spread as MODEL 4. Each infected cell
in this model serves as the transmitter, actively interacting
with other cells [60]. The transmitting cell either 1) pro-
duces EVs (specifically, exosomes) through its intracellular
machinery and releases them upon the fusion of interme-
diate vesicle-containing endosome compartments, referred to
as multivesicular bodies, with the plasma membrane, or 2)
involves vertical trafficking of molecular cargo to the plasma
membrane, a redistribution of membrane lipids, and the use
of contractile machinery at the surface to allow for vesicle
pinching (specifically, microvesicles) [61]. This corresponds to
EVs moving from the intracellular space to the extracellular
space (the propagation medium). The aspects of EV release
yet need to be theoretically investigated addressing infection
factors.
The extracellular matrix (ECM) is the interstitial channel
through which EVs are exchanged between the infected virus-
producing transmitting cells and the target uninfected receiving
cells. The ECM is a 3D molecular network composed of
macromolecules. To reach the targeted cell, both the virions
and virus-associated EVs should navigate around these macro-
molecules and diffuse inside and outside other cells in the
ECM. The Langevin stochastic differential equation (SDE)
can potentially be utilised as a channel modelling tool [6].
Since EVs propagate within the ECM based on a drifted
random walk, the Langevin SDE needs to contain contributions
from the Brownian stochastic force and the drift velocity of
the interstitial fluid. Besides, the Langevin SDE needs to be
modified to address (a) the losses or clearances of EVs via
uptake from other cells and/or degradation through enzymatic
attacks, and (b) the anisotropic EV diffusion affected by the
ECM properties, i.e., volume fraction and tortuosity. The vol-
ume fraction defines the percentage of the total ECM volume
accessible to the virus-bearing EVs. The tortuosity describes
the average hindrance of a medium relative to an obstacle-
free medium. Hindrance results in an effective diffusion that
is decreased compared with the free diffusion coefficient of
EVs.
The receiving cell takes up EVs once they bind to the
cell-membrane utilising one of the three mechanisms: 1)
juxtacrine signalling – where EVs elicit transduction via
intracellular signalling pathways, 2) fusion – where EVs fuse
with the cellular membrane and transfer cargo (i.e., virus-
associated components) into the cytoplasm, and 3) endocytosis
– where EVs internalise and retain in transport vesicles. Non-
linear EV-uptake associated with these various mechanisms
have been initially investigated in terms of EV-based drug
delivery, utilising the Volterra series and multi-dimensional
Fourier analysis [51]. The ability to receive viral loads and
react accordingly can serve as the performance indicator to
reconstruct the information sent by the transmitting cell.
3) Immune System Response: Similar to the virus analysis,
the molecular communications paradigm can give us a clear
understanding of how the immune system acts and develops
within the body over time. Without going into detailed elabo-
ration, we identify the following two systems:
• The Cytokines-based molecular communications system,
which represents cells like macrophages, T-helper cells,
natural killer cells, neutrophils, dendritic cells, mast cells,
monocytes, B cells and T cells, all serving as transceivers;
we refer to modelling cytokines-based molecular commu-
nications system as MODEL 5, and
• The Antibody-based molecular communications system,
which represents cells like plasma B cells and T cells
serving as transmitters, and the virus serving as the
receiver; we refer to modelling antibody-based molecular
communications system as MODEL 6.
The immune system is a complex network of cells and
proteins that defends the body against pathogen infection.
Two subsystems compose the immune system: the innate
immune system and the adaptive immune system. The innate
immune system is referred to as non-specific as it provides
a general defence against harmful germs and substances. The
adaptive immune system is referred to as specific as it makes
and uses antibodies to fight certain germs that the body has
been previously exposed to. The immune system thus works
to eradicate the virus. Considering a detailed role of the
immune system, i.e., the additional mechanisms in fighting
a viral infection V (l) from the innate immune response (IIR)






1 + εpRIIP (t)
I2(t)− cV (l)(t)−
− kV (l)(t)T (t)− hV (l)(t)RAIR(t) (14)
dI1(t)
dt
= kV (l)(t)T (t)− ωI1(t) (15)
dI2(t)
dt
= ωI1(t)− δI2(t) (16)
dT (t)
dt
= rD(t)− kV (l)(t)T (t) (17)
dRIIR(t)
dt
= ψV (l)(t)− bRIIP (t) (18)
dRAIR(t)
dt
= fV (l)(t) + βRAIP (t). (19)
Additional effects are also included: two populations of in-
fected cells – infected but not yet virus-producing cells (I1)
with the duration of latent eclipse phase of 1/ω, and infected
and virus-producing cells (I2), as well as dead cell (D)
replacement by new susceptible cells at a constant rate r. The
IIR (RIIR) frees the virus at a constant rate ψ and dies at
a constant rate b; εp is the strength of innate response. The
AIR (RAIR) is activated proportional to the free viral load at a
constant rate f . Activation is followed by clonal expansion at a
constant rate β. The AIR neutralises the virus with a constant
rate h.
RIIR and RAIR in (18) and (19) represent concentrations
of cytokines and antibodies, respectively. Cytokines are pep-
tides secreted by immune cells (predominantly macrophages,
dendritic cell and T-helper cells) to orchestrate an immune
response or an attack on the invading pathogen (Fig. 2c).
Cytokines spread through the body and attach to surface
receptors of other immune cells. The receptors then signal the
cell to help fight the infection. Cytokines are divided into four
categories – interleukins, interferons, chemokines and tumour
necrosis factors – which can be pro-inflammatory or anti-
inflammatory, thus promoting or inhibiting the proliferation
and functions of other immune cells. Antibodies are unique
proteins encoded by millions of genes which are made and
mutated in the human body. They are secreted by immune cells
(predominantly plasma B cells differentiated from B cells) to
neutralise the pathogen (Fig. 2d). The antibody neutralises the
pathogen by recognising a unique molecule of the pathogen,
called an antigen, via the fragment antigen-binding (Fab)
variable region.
In the context of communications, the cytokines and an-
tibodies are thus considered as information carriers, which
propagate messages from the location of transmission until
the location of the reception. The information conveyed by the
cytokines and antibodies is infection reaction, as a response to
infection action. For both MODEL 5 and MODEL 6, solutions
to RIIR and RAIR should consider the types of specific
immune markers and antibodies per virus as described in Table
IV. These values can be used as initial reference values to
lead the parameter fitting in the model for predicting the time
progression of the innate immune response and the adaptive
immune response. Since this model is relatively new, the
integration of these values may lead to the development of
further modelling that is not covered in this paper.
B. Extra-body Molecular Communications Models
The airborne spread of infection is the main mechanism
of human-human transmission of viruses. Once viruses are
excreted into the air, they propagate towards another person
that inhales them into its lungs. This mechanism allows the
virus infection spreading to local or pandemic levels, which
can occur in a matter of days. There are other modes of human-
human transmission of viruses, including human contact trans-
mission, or sexual transmission, but we do not explore these
modes of transmission in this paper. Our objective in this
section is to explore and analyse the airborne virus molec-
ular communications system. It is comprised of the human
excretion system as the virus transmitter, the propagation of
the virus in the air as the channel, and the human respiratory
system as the receiver.
1) Transmitter: We consider the human as the source of
virus transmission in the air. The infected humans excrete the
virus with a particular concentration rate and velocity via the
respiratory system. The respiratory system is composed of the
nasal/oral cavity, pharynx, larynx, trachea and lungs, which
are comprised of the bronchus and alveolus. Excretion of the
virus starts from the alveolus, and propagation to the bronchus
towards the nasal/oral cavity.
Recent works in the literature have been reporting several
models that describe the release of particles or droplets in
the air by the respiratory system. For example, the model
presented in [19] explores the release of droplets by breath,
sneeze and cough. The authors consider a rate model together
with an event profiler to condition the rates of droplet release
based on the three modes of transmission. The authors are
interested in the steady-state derivations where these three
modes converge to an averaged exhalation process. We believe
that steady-state models do provide attractive mathematical
solutions; however, they do not consider the generation process
of the droplets and phenomena that influence the fate of the
droplets apart from diffusion properties. In a similar goal but
with a different approach, another initial transmitter model
that analyses the air cloud produced by events driven by
exhalation processes was proposed [63]. It withstands the same
issues with the previous model, where the release rates neglect
different phenomena that influence the droplets, and in this
particular case, the cloud and its characteristics. The work
developed in [64] showed that the droplets evolve inside a
turbulent jet transitioning shortly to a puff. Ejected droplets
are surrounded by a dynamically evolving air volume that is
coupled to the droplet trajectory. While the major interest has
been paid to static or averaged conditions of droplets, we argue
that the literature fails to address (a) how the generation of
droplets by the human body is coupled with existing modelling
efforts and (b) how the conditions of the human body of
the infected person impact the exhalation of the droplets
in the air. Therefore, we advocate for the consideration of
biological models, or variables adjusted from them, where the
characterisation of the droplets is thoroughly considered while
having a more detail process of how they are generated.
In this paper, we concentrate on the analysis of three
different modes of transmission models for the virus excretion
processes, which include breathing, coughing and sneezing, as
depicted in Fig. 3. These modes dictate the initial properties of
the virus propagation in the air, which alters the outcome of its
range of propagation and the velocity that the virus diffuses.
In [18], the authors compiled these modes of virus excretion
under one umbrella and referred to them as exhaled breathing.
However, more details should be provided as to how these
different modes of transmission impact virus propagation. We
explain more in the following, where we provide an initial
molecular communications model of this transmission process
which we refer to as MODEL 7.
We consider that the concentration of droplets Di released
by the human transmitter is modelled as a convection process
of virus concentration Vi in the lungs and enters the nasal/oral
cavity with rate kc, representing the virus excretion process.







= ∇V0Dd(∇Vi) + (Vr(t) ~ Pv(t)) (21)
where V0 is the initial concentration of virus in the nasal/oral
cavity, Vr(t), is the rate of virus replication in the lungs, Pv(t)
is the propagation of virus from the lungs to the nasal/oral
cavity, and ~ is the convolution operator. We do not explore
this model in detail, since the detailed version can be found in
[64], [19]. However, we acknowledge that kc is directly linked
with the transmission modes that we discussed earlier (breath-
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Fig. 2. Activation of innate and adaptive immune systems. The cytokine-based- and antibody-based molecular communications systems are shown in Phase
(c) and (d), respectively.
considered to affect the velocity of propagation of droplets. We
argue that they are fundamental in the characterisation of virus
conversion to droplets as well as the rate of released droplets
themselves. Many approaches do consider kc in the steady-
state, but we like to draw attention by the community that it
can have non-linear relationships with the infected humans,
so it should also be associated with different disease stages
over time that is bounded by transition probabilities of stage
changes (severe stage to mild, and vice versa). Moreover, as
shown in both (20) and (21), that non-linearities do exist, for
example, the relationship Vr(t)~Pv(t) is added to the model
but is currently non-existing in the literature. The initial virus
concentration V0 can be directly obtained from values in Table
I. Also Vi and kc can be obtained from [65], [66].
2) Channel: Droplets travel in the air following diffusion
properties bounded by airflow properties. For example, the
modes of transmission discussed above can impact on different
types of turbulent flows that lead to a puff scenario, further
resulting in airflow forces that are weakened and gravitational
forces on the droplet to get stronger. These droplets tend to
travel a few meters away from the human excretion point
(transmitter), which takes around several seconds, and can
reach the human receiving points (e.g., nose or mouth) up to 6
meters of distance. Molecular communications channel models
can be used to model these effects of droplet concentration
release in the air, and possibly be used to characterise the
number of delivered droplets to the human receiving points. In
this section, we review existing models and analyse a general
channel model.
We summarise the literature on existing droplet propagation
models with certain properties of the droplet and airborne
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MODEL 7 MODEL 8
Fig. 3. Molecular communications model of a human transmitter of airborne
viruses. The system is comprised of the virus replication, lung-mouth prop-
agation and virus excretion phases. They dictate the rate and strength by
which the virus is released to the environment that leads to different range
in propagation distance. The sneeze, cough and breath are three different
transmission modes for virus excretion.
viral particles in Table II. Even though they are not entirely
classified as pure molecular communications channels, they
present not only the physical modelling of droplet propagation
but also the effects of droplet propagation and thus can be
considered by the community for characterising Molecular
Communication Systems. We analyse the literature in terms
of the completeness of the physics that govern the droplet
propagation. First, we look at their modes of propagation,
TABLE II
LITERATURE REVIEW SUMMARY ON CHANNEL MODELS FOR VIRUS AIR PROPAGATION
Propagation mode Ref. Medium Turbulent Flow Puff Flow Droplet Evaporation Droplet Crystallisation
Air- [67] Transient Air
based [63] Air Cloud
[68] Single Droplet
Molecular- [69] Particle Dist.
based [70] Concentration
[19] Concentration/Rate
either air-based or molecular-based. These modes dictate the
way these models are constructed. Then, we classify each type
of medium that can be utilised for modelling these molecular
communications approaches. The types of species include
airflow behaviour with average droplet concentration (transient
air, air cloud) to more focused on the characterisation of
the number of droplets (single, distribution, concentration and
concentration/rate). We also analyse the airflow properties
that are mostly secreted from a person as the transmitting
point, this includes turbulent flow and puff flow. Turbulent
flow accounts for the advection-diffusion of particles that are
influenced by a force, in this case, the air turbulence and
flow created from the transmitting point. The puff flow can
be regarded as the Brownian diffusion in the air and can be
influenced by gravity. Lastly, we analyse the properties of
the environment that affects the state of droplets once they
are excreted and this includes evaporation and crystallisation.
Since the majority of the droplets is comprised of water, it
is subject to effects from temperature change that can result
in evaporation, as well as the quantity of salt in the droplet
that lead to its crystallisation. From Table II, we observe that
all species comply with the puff and turbulent flow ([67],
[69], [70], [19]). However, we do recognise that environmental
effects on the droplets are not fully explored for molecular
communications models. The environmental effects have a
significant impact on the propagation of the droplets, as it
can either impact (a) on the flow behaviour in space, or (b)
on the rate of virus reception by the receiving organ (e.g.,
nose or lung). Besides future investigation in environmental
effects on the droplet propagation, there are also needs for
further investigation on the effects of jet streams that affect
the viral propagation behaviour. This includes understanding
the aerodynamic airflow within confined and open areas and
how this affects the flow of the viral particle propagation.
We now describe the propagation model of airborne
droplets, which we refer to as MODEL 8. We assume the
source is located at ~r = [x, y, z] and emits droplets with
rate S(~r, t). Based on the Fick’s second law of diffusion, we






−∇~F − σ, (22)
where ~F is the mass, and σ is the droplet degradation loss de-
rived from environmental effects. There are many approaches
to derive ~F , and this largely depends on the environment. For
example, the authors in [19] focus on expanding the term to
include Fick’s advection and diffusion effects on the flow.
We understand that those terms represent the turbulent flow
and puff flow, respectively. On the other hand, [67] presents a
more complex model based on the aerodynamics of the airflow,
which precisely addresses the turbulent and jet flows that drive
droplet propagation. The authors present the validation of their
model using experimental data.
We show in (22) that σ influences directly the propagation
of droplets from environmental effects such as evaporation
or crystallisation. This is an interesting effect where the
temperature, water content, and the salt crystals concentra-
tion in the droplet jointly impact diffusion and the rates or
concentration when it reaches the receiver. Even though this
phenomenon has been explored before [68], [69], the authors
of [67] investigated this effect, where they derived a model
that couples aerodynamic properties and environmental effects
on the droplet propagation behaviour. Their model was also
validated based on imaging experiments using an ultrasonic
levitator to capture transient dynamics of evaporation and
precipitation of the evaporating droplet.
One of the main advantages of modelling virus propaga-
tion using the molecular communications paradigm is the
derivation of particle propagation rates, which can be used
to study the viral entry mechanism into a human receiver.
In [19], the authors utilised the solution in (22), by breaking
down diffusion components into three dimensions (x, y, z),
and algebraically developing the diffusive and mass matrices
based on wind flow. To derive a closed-form solution, the
authors considered the steady-state response of the breathing
process, where they obtain a closed-form Green’s function.
The obtained closed-form solution for the droplet concentra-
tion is represented as














where η is the turbulence indicator due to wind sources, H
is the height of a person’s mouth to the ground, and u is the
flow velocity in the x dimension.
These models are attractive from the propagation and system
theory point of view. However, the authors do not explore
practical results in terms of infection. During exposure to an
infected human transmitter, several variables dictate the fate
of the human receiver, possibly leading to another infection,
and this can include the time of exposure as well as the
distance between the person emitting the droplets and the
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MODEL 8 MODEL 9
Fig. 4. Molecular communications model of the human receiver of airborne viruses. a) According to the different regions in the respiratory tract, the size of
the particles propagating downwards is smaller; b) The human receiver model is comprised of droplets entrance rate, mouth-lung propagation, virus replication
and deposition rates; c) Alveoli sack and alveoli with moderate and severe mucus presence due to infection progression; d) The virus duplication process; e)
The virus deposition process.
this end-to-end scenario, where the probabilities of infection
at the human receiver are evaluated in terms of distance, time
of exposure, and coughing angle. As droplets propagation
is bounded by the angle of release, it is also important to
incorporate spatial analysis on the infection probability, such
as the coughing angle.
3) Receiver: In the human receiver, the airborne droplets
are absorbed by the nasal-mouth cavity and propagate along
the respiratory tract until they reach the alveoli. During this
path, the virus undergoes replication, penetrating deep into
the epithelial tissues, and then into the circulatory system to
infect other organs and systems. In this section, we focus on
the high-level modelling and analysis focused on the infection
process through the human respiratory tract virus propagation.
Modelling the human receiver using a systems theory ap-
proach can be increasingly complex since there are two main
factors that, individually, comprise of several steps. First, there
is the entrance of the droplets containing viruses into the
human body and residing in the lungs. Secondly, there is the
infection process of internal progression. The model for the
viral entry can be found in [20], which accounts for virus
dispersion along the respiratory tract impacted by factors such
as the respiratory rate, viral exposure levels (i.e., the quantity
of virus that is inhaled), and the virus particle size. The
authors developed a computational model to account for the
changes in the virus propagation as it enters and propagates
in the respiratory tract. For the virus infection process, [20]
also considers the impact of the immune system and how it
influences the overall concentration of the virus within the
respiratory tract. The model in [63] focuses on a high-level
generic approach based on probability of infection calculated
from the probability of reception of droplets containing the
virus. Both models are different in terms of biological details
or probabilistic infection estimation solutions. We not only
support their integration, and creating a scenario where the
probability of infection is dependent on increased biology
realism, but also for these models to contribute towards
modelling the progression of infection and state of infectivity.
Understanding the end-to-end propagation to the infectivity
process is a crucial contribution for researchers, because this
can lead to insights of molecular interactions at the cellular
level and the impact of the infection on subsystems of the
body, which in turn can lead to precision medicine in clinical
decisions for treatments and patient recovery guidelines.
Our analysis on the viral impact on the human receiver
model is depicted in Fig. 4, which we refer to as MODEL 9.
There are three main blocks in the model: the droplets entrance
rate, the mouth-lung propagation, and the virus replication and
deposition rates. The general model of virus propagation is
based on a governing equation based on the Fick’s second
law for advection-diffusion investigated in [20]. This model
accounts for the concentration of the virus in a particular









− (p− k)Gi(x, t)
(24)
where i is the generation number (i = 0, 1, 2, 3, ...23) of the
lung branches, k is the virus deposition rate, p is the virus
replication rate, D is the diffusion coefficient, and x is the
direction of the virus propagation (downward or upward in
the respiratory tract). The Gi(x, t)|t=0 represents the droplet
entrance rate. Fig. 4d and Fig. 4e depicts the replication and
deposition of the virus, respectively. The authors in [20] also
explored the dynamics change in the viral pleomorphic size
changes during the propagation. The advection-diffusion com-
ponent is used to model the breathing process to understand
the airflow into the lung. Even though they concentrate on
COVID-19, it is clear that their proposed model can be applied
to other virus types that propagate through the respiratory tract.
For the future, such models may need not only experimental
validation, but further integration with infection development
itself. As shown in Fig. 4c, the changes in the virus infection
process for SARS-CoV-2 (e.g., from moderate to severe), can
present changes in the volume of mucus present in the alveolus
and the entire respiratory tract. This infection process can not
only produce changes in the breathing rhythms and cough rate,
but it can also change the advection-diffusion process within
the lung generation. As the virus penetrate areas with a high
quantity of mucus, the propagation medium changes enough to
make the advection property of virus flow to dramatically re-
duced. Moreover, the deposition and replication rates changes
within the mucus areas. This, in turn, can affect the binding
process of the virus, which is different for pure diffusion in
air pockets compared to a space with mucus. One interesting
development could be the investigation of stochastic diffusion
coefficients, deposition rates and replication rates of the virus,
and how this evolves as the mucus production increases using
a multi-medium molecular communications model. The initial
virus concentration Gi can be directly obtained from values
in Table I. Also k, p and D can be obtained from [65], [66].
IV. LEVERAGING EXPERIMENTAL DATA FOR MOLECULAR
COMMUNICATIONS
The molecular communications community has been ab-
stracting cellular signalling for more than a decade of active
research, replicating the characterisation of the functions of
wired and wireless networking and computing systems. How-
ever, with only a few experimental demonstration systems
reported to date [71], [72], the molecular communications
field generally lacks validation aspects. We anticipate similar
challenges to arise when building molecular communications
models of the virus intra-body and extra-body propagation,
which are critically needed to understand virus dynamics and
unveil new insights that will increase our understanding of
virus pathogenesis and enable spread and infection patterns
to be more predictable in vivo. To characterise the viral dy-
namics and evolution, one of the initial generic computational
modellings demonstrated the necessity to integrate biophysical
models and infection properties [20]. In this section, we
discuss many sources of open data that can be used to be
incorporated into the models presented in the previous section,
and that can inspire the molecular communications community
to produce new models. The link between the presented
models and the experimental data is summarised in Table III,
where we present what experimental data should be used for
each model and where to find such data.
Biophysical models present real physiological parameters
associated with the physical space where the virus propagates
through. These parameters are typically available in the lit-
erature to be readily used by the molecular communications
community for in silico modelling. The examples include the
TABLE III
SUMMARY OF THE LINK BETWEEN THE PRESENTED MODELS AND
EXPERIMENTAL DATA
Model Experimental Data Availability
1 Airflow profile, diameter and length of
each airway, virus concentration pro-
files
Table I, [65]
2 Blood velocity profile, diameter and
length of each vessel generation, virus
concentration profiles
Table I, [73]
3 Virus proliferation rates None
4 Virus proliferation rates None
5 Cytokine and antibody concentration
levels
Table IV
6 Cytokine and antibody concentration
levels
Table IV
7 Airflow profile, diameter and length of
each airway, ACE2 receptor biding rate
Table I, [65],
[66]
8 Airflow profile, diameter and length of
each airway
Table I, [65]
9 Airflow profile, diameter and length
of each airway, blood velocity profile,
diameter and length of each vessel,
genome, proteome, RNA transcripts,
ACE2 receptor biding rate
Table I, [65],
[73], [66]
analysis of entry and spread of SARS-CoV (1-2) and MERS-
CoV in the respiratory system, where MODEL 1 and MODEL
7-9 require values for the airflow profile, and diameter and
length of each airway generation available from [65]. For the
analysis of entry and spread of DENV, ZIKV and HCV in the
circulatory system, MODEL 2 AND MODEL 9 require values
for the blood velocity profile, diameter and length of each
vessel generation available from [73].
The basic set of infection properties includes viral exposure
levels (in different specimens), virion characteristics, and
how viruses interact with cells and the immune system. We
summarise relevant data for SARS-CoV (1-2), MERS-CoV,
EBOV, DENV, ZIKV and HCV in Table I and Table IV. Apart
from exposure levels and virion characteristics (including their
genome, proteome and RNA transcripts), Table I identifies
detection methods, whereas Table IV outlines the infection
impact and immune markers for each of the considered viruses.
This information is necessary for the effects on the receiver
communication models, or MODEL 9, where the interactions
between virus-host cells are found.
Based on the available data, at least the concentration
profiles of each of these viruses given in Table I, SARS-
CoV (1-2), MERS-CoV and ZIKV translocation across the
epithelium, or MODEL 1, and EBOV, DENV, ZIKV and HCV
spread via the bloodstream, or MODEL 2, can be initially
analysed. One way of doing such analyses is to associate
the available concentration profiles given in Table I with Vo
given in (1) of MODEL 1 and V (b) given in (7) of MODEL
2, respectively, and assume initial values for other relevant
concentration profiles occurring in (1)-(3) and (7)-(11). In
addition, the parametric values for the virus interaction with
the host cells and immune system cells, e.g., forward- and
backward reaction rates, are still unavailable and need to
be assumed. Obtaining these values from the experiments
is challenging but can lead to accurate predictions of viral
TABLE IV
VIRAL INFECTION IMPACT AND IMMUNE MARKERS FOR ENTRY POINTS
Type Infection impact Specific immune markers Specific antibodies Ref.
SARS-CoV
(1-2)
Initiates by the attachment of ACE2
glycoprotein to host receptors
SARS-CoV-2: Lower CD4, CD8, NK cell counts, PD-1,
Tim-3 on T cells, Phenotype change in monocytes, IP-10,
MCP-3, IL-1RA, IL-6, IL-8, IL-10, IL-2R, IL-1β, IL-4,
IL-18, GM-CSF, IL-2 and IFN-γ
Neutralising IgG antibod-
ies that target internal N




MERS-CoV Initiates by the attachment of a glyco-
protein to host DPP4 receptor
IFN-α, IL-12, IL-17, IFN-γ RBD of S protein [76]
EBOV Initiates by the attachment of glycopro-
tein to host receptors
IL-1β (high), TNF-α (high), IL-6 (high), IL-1RA, sTNF-
R (high), SIL-6R, MIP-1α, MIP-1β, Neopterin, SAA,
NO2-, Cortisol, IL-10




DENV Initiates by glycoprotein E protein bind-
ing to DC-SIGN, a C-type lectin
IFN-α, IL-6, IL-15, TNF-α, IL-1RA, CXCL8, CCL3,
CCL4, CCL5, CCL11, M-CSF, G-CSF, ICAM-1, L-
Selectin, P-Selectin, CD40, CD40L, Fas, FasL, TRAIL-







ZIKV Initiates by the attachment of the viral
glycoprotein E protein to host receptors





HCV Initiates by E2 protein interacting with
cell surface heparan sulfate proteogly-
cans
CD127+CD8+ T cells, CD127-CD8+ T cells,
CD161+CD8+ T cells, PD-1, Regulatory CD4+
and CD8 T cells, IL-10, CXCR3, CXCR6






More advanced modelling approaches also operate with
the host cell surface receptor distribution, host cell distribu-
tion, replication and deposition rates, and immune-response-
relevant parameters. For example, in the case of SARS-CoV-
2, the virions use the ACE2 receptor to bind to and enter
host cells (Table IV), which is important for MODEL 7 and
MODEL 9. The density of ACE2-expressing host cells is
modelled in the literature to follow the Gaussian distribution
(e.g., N (5.83, 0.71) (Copies/mL)) [66]). Spatial distributions
additionally complicate the molecular communications mod-
elling since ACE2-expressing host cells are not spread evenly,
thus creating a heterogeneous concentration distribution across
the respiratory system [20]. Other parameters relevant for the
target-cell model (presented in Section III-A) that facilitate
binding by SARS-CoV-2 virus in the respiratory systems can
be found in [85], [86]. The overview of the infection impact
of other considered viruses is also given in Table IV.
In the case of virus proliferation via neurons and EVs, no
relevant data for MODEL 3 and MODEL 4 have been collected
in the tables. We thus advocate for the need to conduct
relevant experiments and back up the corresponding molecular
communications models that are yet to be developed. As of
the immune system reaction via cytokines and antibodies,
we list the relevant immune markers and antibodies for each
of the considered viruses in Table IV. The corresponding
concentration levels are typically available in the literature,
e.g., cytokine levels in SARS-CoV [87], [88], [89], and can
be used to support MODEL 5 and MODEL 6.
The airborne virus propagation models through droplets
based on MODEL 8 need a set of data to characterise diffusion
properties when a human transmitter sneezes, coughs or talks.
The availability of this data is a critical issue as we found
very limited resources that can be used. However, existing
testbeds can be used to generate data that can be used by the
molecular communications researchers. A particular testbed
that is appropriate for this scenario is the Tabletop Molecular
Communication [72], where the authors presented the release
of isopropyl alcohol molecules through an electronic-activated
spray. These airborne molecules flow towards an alcohol
sensor through the airflow produced by a fan. The authors
demonstrate the successful encoding, transmission and recep-
tion of information encoded using molecules concentration.
This testbed can be used to study the effects of droplet
propagation, i.e., coupling it with MODEL 8. The usage of
fans can provide modifications to the airflow that drives the
propagation of the droplets, and hence air jet streams found in
different indoor or outdoor scenarios. This would help estimate
parameters for velocity and turbulence measures, such as η and
u in (23). The production of droplets is not clear, especially
when trying to emulate events of sneeze, cough and speech.
However, we believe the testbed can be extended to include
different versions of the electronic-activated spray that can
modulate the release rate of molecules, for example. In that
way, parameter S(~r, t) in (22) would be associated with a
proper virus release rate profile in each emulated event. Lastly,
the propagation of the droplets itself can be used to determine
other model parameters including the droplet degradation loss
derived from environmental effects, which is σ in 22. The
value of σ can be broken down into different components as
shown in Table II, where the testbed can be used to estimate
σ.
Other sources of open data, specifically for COVID-19,
include studies presented in [90] and [91]. They offer a wide
range of information for genetic sequences for both viruses
and hosts, genetic expressions, protein, biochemistry and even
imaging. Apart from the latter, all others can be integrated
into all models discussed in this paper. On the other hand, the
position paper given in [92] summarises a large number of
studies on the formation of virus-laden aerosol particles and
their spread. This paper presents many interesting effects to
aerosol propagation that were not discussed here, including
ventilation systems and the effectiveness of the usage of
masks. Lastly, the dataset presented in [93] explores the usage
of laser particle counter to measure the emission of aerosol
particles during speaking, singing and shouting activities.
V. OPEN ISSUES AND CHALLENGES
In this section, we explore the open issues and challenges
derived from the discussion presented in our survey so far. Our
vision is that molecular communications aligns itself further
with the area of bioengineering so that models of methods
can be verified by experiments, working in close collaboration
with relevant experts. We explore linking of experimental data
to molecular communications models, novel intra-body viral
intervention techniques, emerging technologies for infection
theranostics, bridging molecular communications and bioin-
formatics, and novel molecular communications models.
A. Linking Experimental Data to Molecular Communications
Models
As discussed, molecular communications needs to provide
further integration of its models with experimental data, either
already available or through novel experiments. The vali-
dation of existing models will be of major benefit to the
community as it helps calibrate the works already developed,
to be directly applicable to the interpretation or prediction
of in vitro or even in vivo phenomena. Without validation,
molecular communications models are likely prevented from
expanding its usage to other areas of potential applications.
There are already some interesting works of how molecular
communications and experimental data can be integrated into
different scenarios and for different applications. For example,
models with experimental data can be found for calcium
signalling [94], [95], bacteria communication [96], [97], [15],
neural communication [98], and macro particle diffusion [72],
[99]. Other works have made great usage of experimental
data, such as data extracted from open source databases and
integrated into their Molecular Communication models, and
examples include works in [100], [101].
The reader must consider referring to all the data provided in
Section IV and the references provided for data acquisition for
new models of infection using the molecular communications
paradigm. Specifically, transmitter designs would benefit from
the process of genetic information encoding with data from
Table I. Propagation of viruses can be based on the diffu-
sion information in different medium provided in the same
table. Lastly, the receiver design directly benefits from the
information provided in both tables. If the receivers are based
on electronic technology, the reader is referred to I, but if
the receivers are actual biological-based devices (e.g., lung
cells), the reader is referred to IV. However, the data provided
here are not sufficient to derive all the necessary variables for
required non-linear models with complex behaviour, and for
that, the reader should consider them as a guiding basis for the
correct understanding of the communication parts involved in
molecular communications for infections diseases.
B. Novel Intra-body Viral Intervention Techniques
Even with the existing efforts in designing vaccination and
drugs for viral infections treatment, there is still a need for
novel interventions requiring robust intra-body solutions [3].
The main reasons are twofold: 1) the effectiveness of vaccines
is not always optimal, and 2) there are consequences to tissues
and organs during the infection that might require repairing
procedures [3]. Stem cell-based treatment is a novel intra-
body solution that has been argued as a leading technology
for future intervention. This technology is used in different
ways, e.g., can be used for drug delivery, and as regenerative
therapy (studies have shown that stem cells can modulate
the immune system for patients suffering from SARS-CoV-
2 infection). Particular stem cells can be derived from many
tissues types, including umbilical cord bone marrow, trabecular
bone, synovial membrane, and fetal tissues such as lung, pan-
creas, spleen, liver, etc. [102], [103], [104]. By interacting with
the media through chemical agents, stem cells can eliminate
existing pathogenic behaviours and repair the tissue or organ.
More specifically, mesenchymal stem cell-based approaches
have been proposed for interventions in many viral infections,
including hepatitis [3], [105], and SARS-CoV [106], [107].
Mesenchymal stem cells are adherent, Fibroblast-like cells
with the ability of self-renewal and differentiation into multiple
cell lineages such as Osteoblasts, Chondrocytes, Adipocytes,
and Hepatocytes. Looking at specific lung-damaging infec-
tions, Mesenchymal stem cells can secrete IL-10, hepato-
cyte growth factor, Keratinocytes growth factor, and VEGF
to alleviate Acute Respiratory Distress Syndrome (ARDS),
regenerate and repair lung damage and resist Fibrosis [106],
[108], [109]. This opens new possibilities for the development
of novel molecular communications solutions that look at
communications between the Mesenchymal stem cells sig-
nalling and its process of repairing damaged tissue from
the communication process. Similar approaches have been
proposed in the community, where Exosome Vesicles (EVs)
were used to model the interactions between stem cells and
Glioblastoma [51], [60]. Even though EVs are also suggested
for the treatment of lung damage [106], we recognise that
different types of signalling information carriers can be used
to create a multi-carrier, or multi-molecules communication
system, serving as ways to increase the overall treatment
capacity.
C. Emerging Technologies for Infection Theranostics
In the intersection of fields such as bioengineering, mate-
rial sciences, and medical sciences lies the development of
innovative technology that can lead to efficient treatment or
diagnosis of infectious diseases, herein referred to as infection
theranostics. Molecular communications can play a role in
these emerging technologies by integrating communications
properties of transmission, propagation and reception. For
example, microfluidic-based organ-on-a-chip devices provide
experimental models of transmission, propagation and recep-
tion of molecules from cell-cell, tissue-tissue and even organ-
organ, with or without other external molecular agents [110].
Another example is the airborne viral detection from biosen-
sors that can be either integrated into all-in-one devices [18] or
integrated biosensors with proposed emerging infrastructures
for 6G, such as the Intelligent Reflecting Surface [111]. In
this case, virus macro-scale propagation and its reception,
through either binding-ligand proteins or electrically charged
droplets, can include modelling expertise from molecular
communications researchers to develop such infrastructures. In
the following, we dive deeper into this topic using the above-
mentioned examples.
Microfluidic-based organ-on-a-chip are alternative experi-
mental models compared to conventional in vitro and ani-
mal models, since they capture many tissue structures that
are found in human organs [112]. The presented literature
investigates how organ-on-a-chip can be used to study virus-
host interactions, viral therapy-resistance evolution, and de-
velopment of new antiviral therapeutics, as well as underlying
pathogenesis. This can be applied to different organs of the
human body; for example, infection models have been applied
to liver chip [113], gut chips [114], [115], neural chips
[116] and lung chips [117], [118]. Molecular communications
models of microfluidic-based organ-on-a-chip can be used to
develop future infection assays to study virus-induced diseases
in real-time and at high resolution. Molecular communications
can aid in inferring methods of disease communication and
progression by analysing how cellular molecular functions
operate in both healthy as well as infectious states. This can be
further extended to design novel molecular modulation mecha-
nisms are used either to augment cellular communication or to
understand effects from external molecular signals, such as a
viral drug. Within the molecular communications community,
there are a number of existing research on microfluidics mod-
elling and experiments [119], [120], and this can be extended
to utilise organ-on-a-chip devices for viral theranostics.
Molecular communications models can be used to design
the sensitivity of the binding process for airborne viral detec-
tion technology. The key principle is to couple the modelling
of air particle flow (as discussed in Section III-B) with the re-
ceiver design, which in this case is an airborne viral biosensor.
These biosensors can be built in a number of ways, including
ligand-binding protein receptors [111], electrically charged
particles [18], CMOS-coupled immunological assays, and even
through Polymerase Chain Reaction (PCR) technology [121].
The receiver design for biosensor technology based on a
realistic propagation model of viral particles is missing. For
example, in an outdoor space, the propagation of the airborne
viral particles can undergo stochastic propagation patterns due
to the changes in airflow directions and turbulence. Therefore,
the design of the biosensor receptor structure can incorporate
molecular communications model to help enhance the design
of the sensors that is appropriate for the specific environ-
ment. However, this will require considerable experimental
work where molecular propagation flow can be studied with
fluorescent technology, similar to the works proposed in [67],
[122], [123], in order to characterise the propagation patterns.
D. Bridging Molecular Communications and Bioinformatics
Tools
In this paper, we mostly investigated the Molecular Com-
munication models of viral infection, but in Section IV, we
explored the link between these models to currently available
experimental data for viral-host genetic interactions. There
exist many interesting works that cover the analysis of these
interactions coming from a bioinformatics perspective, which
can analyse a large number of protein interactions and how
they affect cells activity and fate [124], [125], [126].
Bioinformatics is a very advanced area in the analysis of
genomics, as previously noted, with several tools and data
available for researchers who desire to investigate the genetic
relationships of viruses and host cells. Based on the genomic
sequencing, these tools can provide the assembly of frag-
mented sequenced data, phylogenetic analysis of taxonomic
groups, identification of genetic structures, identification of
domains, functions and metabolic pathways, as well as data
sharing capabilities [124]. Researchers in the area are hoping
that, by having open-shared data and tools access policy, they
facilitate the discovery of targeted genes and what leads to
cell behaviour [127]. Some works focus on the discovery of
new drugs or even vaccines [125], [126]. Even though some
exciting works related to the topic of genomics are presented
in the molecular communications field [17], [128], [129], the
total and practical integration of molecular communications
and bioinformatics tools are far from being explored. More
works linking genomics with cell behaviour can solve existing
issues, including the characterisation of natural cell signalling
modulation techniques, sources of noise and interference,
encoding/decoding of molecular information, and synthetic
molecular communications. The bioinformatics existing tools
already provide the information on the cell genetics and,
sometimes, linkage to cell behaviour. Seamless integration
with molecular communications leads to studies such as on
the interaction of viral DNA content [17] and techniques
for linking DNA exchange between bacteria for bacteria-
based molecular communications [128]. Looking at the various
models and systems presented in this paper, we advocate that
the viral genetic interactions with host cells can provide novel
understandings on how infected cells propagate the genetic
content to other cells from an information and communication
theory approach, while at the same time also considering the
evolution of the genetic content, which can provide novel
mechanisms for inferring infection propagation inside the
body.
E. Novel Molecular Communications Models
New advancements in molecular communications modelling
are needed, from this point in time forward, to help understand
the virus propagation both intra-body and extra-body and the
end-to-end communication system. For intra-body, the link
between virus replication and tissue response has yet to be
thoroughly investigated. For example, the interactions of the
virus with neural communications [130], [13], or calcium sig-
nalling in different tissues or organs (especially the epithelium)
[131], [132], [133], can provide further understanding between
the virus and hosts interactions using molecular signals as
infection information carriers. As we know from the literature,
the human immune response is triggered after the human body
recognises the presence of infectious agents, foreign to the
body itself [134]. The immune response is yet to be explored
using concepts from molecular communications, similar to the
models initially discussed in Section II, and to tie this to other
Molecular Communication models (e.g., propagation within
the circulatory system), in order to create an end-to-end system
model. The key benefit of these studies is the ability to accu-
rately capture the effects of viral propagation communication
on the immune response communication, which would create
computational models that can benefit vaccine designers in the
future if the various sub-communication systems and interac-
tions are well understood. These new models could be used
to analyse new techniques to modulate the immune system
response, coming from a regenerative medical intervention,
based on the precise calculation of infections stages derived
from virus-host interactions, in order to lead to an end-to-end
diagnostic and therapeutic strategy for vaccine development.
For extra-body models, where models have recently been
introduced on airborne droplet propagation, there are further
developments required. First, transmitter models for extra-
body molecular communications should consider in more
detail the conditions of the human transmitter, i.e., the level
of infection and condition of the respiratory system. This
understanding can provide new relationships between the
virus release rates from the host, and the analysis of viral
reception concentration by another host. In the receiver, as
explored in Section III-A, the need to couple models of the
propagation of the respiratory tract, with actual rates derived
from the airborne droplet propagation models are needed. This
will contribute towards and end-to-end model that considers
the Molecular Communication airflow propagation coupled
with environmental effects on the droplets, and to link this
with the intra-body propagation of the virus into the lungs.
Even though an end-to-end analysis of these systems can
lead to increasingly complex models, they can be useful in
accurately predicting infection spreading patterns, and how
this can impact on people with different health conditions,
in order to personalise and classify their risk levels. Such
accurate modelling can prevent total lockdowns for the entire
society, where people in different categories can be allowed
into society provided they take certain protective measures.
VI. CONCLUSIONS
Molecular communications can play a significant role in
viral infectious disease research, by considering the detail
characterisation of the transmission, reception and propa-
gation of viruses inside and outside the human body. We
provided an extensive review of the existing literature on the
topic, by analysing the existing models for intra-body and
extra-body molecular communications. For intra-body mod-
els, we explored the viral translocation across the epithelial
and endothelial barriers, neurotropic viral spread, EV-based
viral spread, cytokine-based- and antibody-based molecular
communications. In extra-body models, we analysed models
for the transmission process of viruses spelt from a human
transmitter, the airborne droplet and virus propagation coupled
with many environmental effects including turbulent flow,
puff flow, droplet evaporation and droplet crystallisation, and
finally, the reception process of viruses in the human receiver.
Besides, we reviewed models for the virus entrance mecha-
nism focusing on the virus concentration in the respiratory
tract. We showed how the available experimental data can be
integrated into molecular communications models, and what
are the open issues and future directions. We are looking
forward to exciting new research that can come as an output of
the interdisciplinary works using molecular communications
for developing new methods for treatment of infection as well
as vaccination methods. Based on the analysis provided in
the paper, we are confident that fantastic novel research can
emerge and help in the fight against the current and future
pandemics.
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The Lancet, vol. 389, no. 10068, pp. 505–518, 2017.
[29] C. I. Yu and B.-L. Chiang, “A new insight into hepatitis C vaccine
development,” Journal of Biomedicine and Biotechnology, vol. 2010,
2010.
[30] J. Peiris, C. Chu, V. Cheng, K. Chan, I. Hung, L. Poon, K. Law,
B. Tang, T. Hon, C. Chan et al., “Clinical progression and viral load
in a community outbreak of coronavirus-associated SARS pneumonia:
a prospective study,” The Lancet, vol. 361, no. 9371, pp. 1767 – 1772,
2003.
[31] I. F. N. Hung, V. C. C. Cheng, A. K. L. Wu, B. S. F. Tang, K. H. Chan,
C. M. Chu, M. M. L. Wong, W. T. Hui, L. L. M. Poon, D. M. W. Tse
et al., “Viral loads in clinical specimens and SARS manifestations,”
Emerging infectious diseases, vol. 10, no. 9, pp. 1550–1557, 2004.
[32] Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, and Q. Wang, “Viral load
of SARS-CoV-2 in clinical samples,” The Lancet Infectious Diseases,
vol. 20, no. 4, pp. 411–412, 2020.
[33] K. K.-W. To, O. T.-Y. Tsang, W.-S. Leung, A. R. Tam, T.-C. Wu,
D. C. Lung, C. C.-Y. Yip, J.-P. Cai, J. M.-C. Chan, T. S.-H. Chik
et al., “Temporal profiles of viral load in posterior oropharyngeal saliva
samples and serum antibody responses during infection by SARS-
CoV-2: an observational cohort study,” The Lancet Infectious Diseases,
vol. 20, no. 5, pp. 565–574, 2020.
[34] L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu,
M. Kang, Y. Song, J. Xia et al., “SARS-CoV-2 viral load in upper
respiratory specimens of infected patients,” New England Journal of
Medicine, vol. 382, no. 12, pp. 1177–1179, 2020.
[35] B. E. Pickett, E. L. Sadat, Y. Zhang, J. M. Noronha, R. B. Squires,
V. Hunt, M. Liu, S. Kumar, S. Zaremba, Z. Gu et al., “ViPR: an open
bioinformatics database and analysis resource for virology research,”
Nucleic acids research, vol. 40, no. D1, pp. D593–D598, 2012.
[36] M.-d. Oh, W. B. Park, P. G. Choe, S.-J. Choi, J.-I. Kim, J. Chae, S. S.
Park, E.-C. Kim, H. S. Oh, E. J. Kim et al., “Viral load kinetics of
MERS coronavirus infection,” New England Journal of Medicine, vol.
375, no. 13, pp. 1303–1305, 2016.
[37] A. R. Fehr and S. Perlman, “Coronaviruses: an overview of their
replication and pathogenesis,” in Coronaviruses. Springer, 2015, pp.
1–23.
[38] S. Al Hajjar, Z. A. Memish, and K. McIntosh, “Middle east respiratory
syndrome coronavirus (MERS-CoV): a perpetual challenge,” Annals of
Saudi medicine, vol. 33, no. 5, pp. 427–436, 2013.
[39] J. S. Towner, P. E. Rollin, D. G. Bausch, A. Sanchez, S. M. Crary,
M. Vincent, W. F. Lee, C. F. Spiropoulou, T. G. Ksiazek, M. Luk-
wiya et al., “Rapid diagnosis of Ebola hemorrhagic fever by reverse
transcription-PCR in an outbreak setting and assessment of patient viral
load as a predictor of outcome,” Journal of Virology, vol. 78, no. 8,
pp. 4330–4341, 2004.
[40] M.-A. de La Vega, G. Caleo, J. Audet, X. Qiu, R. A. Kozak, J. I.
Brooks, S. Kern, A. Wolz, A. Sprecher, J. Greig et al., “Ebola viral load
at diagnosis associates with patient outcome and outbreak evolution,”
The Journal of Clinical Investigation, vol. 125, no. 12, pp. 4421–4428,
12 2015.
[41] R. Ben-Shachar, S. Schmidler, and K. Koelle, “Drivers of inter-
individual variation in Dengue viral load dynamics,” PLOS Compu-
tational Biology, vol. 12, no. 11, pp. 1–26, 11 2016.
[42] W.-K. Wang, D.-Y. Chao, C.-L. Kao, H.-C. Wu, Y.-C. Liu, C.-M. Li,
S.-C. Lin, S.-T. Ho, J.-H. Huang, and C.-C. King, “High levels of
plasma Dengue viral load during defervescence in patients with Dengue
Hemorrhagic Fever: Implications for pathogenesis,” Virology, vol. 305,
no. 2, pp. 330 – 338, 2003.
[43] W. K. Wang, H. L. Chen, C. F. Yang, S. C. Hsieh, C. C. Juan, S. M.
Chang, C. C. Yu, L. H. Lin, J. H. Huang, and C. C. King, “Slower
rates of clearance of viral load and virus-containing immune complexes
in patients with Dengue hemorrhagic fever,” Clin Infect Dis, vol. 43,
no. 8, pp. 1023–30, 2006.
[44] J. M. Mansuy, M. Dutertre, C. Mengelle, C. Fourcade, B. Marchou,
P. Delobel, J. Izopet, and G. Martin-Blondel, “Zika virus: high infec-
tious viral load in semen, a new sexually transmitted pathogen?” The
Lancet Infectious Diseases, vol. 16, no. 4, p. 405, 2016.
[45] F. de Laval, S. Matheus, T. Labrousse, A. Enfissi, D. Rousset, and
S. Briolant, “Kinetics of Zika viral load in semen,” New England
Journal of Medicine, vol. 377, no. 7, pp. 697–699, 2017.
[46] C. Fourcade, J.-M. Mansuy, M. Dutertre, M. Delpech, B. Marchou,
P. Delobel, J. Izopet, and G. Martin-Blondel, “Viral load kinetics of
Zika virus in plasma, urine and saliva in a couple returning from
Martinique, French West Indies,” Journal of Clinical Virology, vol. 82,
pp. 1 – 4, 2016.
[47] H. Lerat, S. Rumin, F. Habersetzer, F. Berby, M. A. Trabaud, C. Trépo,
and G. Inchauspé, “In vivo tropism of hepatitis C virus genomic se-
quences in hematopoietic cells: influence of viral load, viral genotype,
and cell phenotype,” Blood, vol. 91, no. 10, pp. 3841–3849, 1998.
[48] J. Louten, “Virus transmission and epidemiology,” Essential Human
Virology, pp. 71–92, 2016.
[49] M. Bomsel and A. Alfsen, “Entry of viruses through the epithelial
barrier: pathogenic trickery,” Nature Reviews Molecular Cell Biology,
vol. 4, no. 1, pp. 57–68, 2003.
[50] Y. Cong and X. Ren, “Coronavirus entry and release in polarized
epithelial cells: a review,” Reviews in medical virology, vol. 24, no. 5,
pp. 308–315, 2014.
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